Day : Friday
Date: 2/23/2007

Time: 18:07:37

PALM INTRANET

Inventor Information for 10/809192

Inventor Name	City	State/Country
REDDY, MANNE SATYANARAYANA	HYDERABAD	INDIA
RAJAN, SRINIVASAN THIRUMALAI	HYDERABAD	INDIA
RAO, UPPALA VENKATA BHASKARA	HYDERABAD	INDIA
REDDY, KONDA SRINIVASA	HYDERABAD	INDIA

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity/Reexam | Foreign

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS  4  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS  5  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS  6  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS  7  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available
 NEWS  8  NOV 20   CA/CAplus to MARPAT accession number crossover limit increased
                   to 50,000
 NEWS  9  DEC 01   CAS REGISTRY updated with new ambiguity codes
 NEWS 10  DEC 11   CAS REGISTRY chemical nomenclature enhanced
 NEWS 11  DEC 14   WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 12  DEC 14   GBFULL and FRFULL enhanced with IPC 8 features and
                   functionality
 NEWS 13  DEC 18   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS 14  DEC 18   CA/CAplus patent kind codes updated
 NEWS 15  DEC 18   MARPAT to CA/CAplus accession number crossover limit increased
                   to 50,000
 NEWS 16  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS 17  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS 18  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 19  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 20  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS 21  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 22  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS 23  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS 24  JAN 29   PHAR reloaded with new search and display fields
 NEWS 25  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases
 NEWS 26  FEB 13   CASREACT coverage to be extended
 NEWS 27  Feb 15   PATDPASPC enhanced with Drug Approval numbers
 NEWS 28  Feb 15   RUSSIAPAT enhanced with pre-1994 records
 NEWS 29  Feb 23   KOREAPAT enhanced with IPC 8 features and functionality

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
```

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:41:35 ON 23 FEB 2007

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:41:53 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4
DICTIONARY FILE UPDATES: 22 FEB 2007 HIGHEST RN 922800-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10809192.str



chain nodes :
7 20 21 22 23 24 25 26 27 28
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13 14 15 16 17 18 19
chain bonds :
6-7 7-8 7-14 11-28 17-20 20-21 21-22 22-23 23-24 24-25 24-26 25-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 14-15 14-19
15-16 16-17 17-18 18-19
exact/norm bonds :
7-14 14-15 14-19 15-16 16-17 17-18 17-20 18-19 21-22 22-23
exact bonds :
6-7 7-8 11-28 20-21 23-24 25-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13 24-25 24-26

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sam
SAMPLE SEARCH INITIATED 18:42:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       18 TO ITERATE

100.0% PROCESSED       18 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          106 TO      614
PROJECTED ANSWERS:               4 TO      200

L2            4 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 18:42:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      374 TO ITERATE

100.0% PROCESSED      374 ITERATIONS                               41 ANSWERS
SEARCH TIME: 00.00.01

L3           41 SEA SSS FUL L1

=> FIL CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31
```

FILE 'CAPLUS' ENTERED AT 18:42:23 ON 23 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Feb 2007 VOL 146 ISS 10
FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3
L4          1053 L3

=> S (CRYSTALLINE)
L5         77110 (CRYSTALLINE)

=> S (L4)
L6          1053 (L4)

=> S L6 AND (CRYSTALLINE)
           77110 CRYSTALLINE
L7             5 L6 AND (CRYSTALLINE)

=> S L6 AND (MONOHYDROCHLORIDE)
            3690 MONOHYDROCHLORIDE
L8             4 L6 AND (MONOHYDROCHLORIDE)

=> S L6 AND (XRAY)
            4684 XRAY
L9             0 L6 AND (XRAY)

=> S L6 AND (X-RAY)
         1574267 X
         1063009 RAY
          821830 X-RAY
                   (X(W)RAY)
L10            5 L6 AND (X-RAY)

=> S L6 AND (DIFFRACTION)
          446102 DIFFRACTION
L11            4 L6 AND (DIFFRACTION)

=> s l7 or l8 or l10 or l11
L12           10 L7 OR L8 OR L10 OR L11

=> s l12 not (2006/so or 2005/so)
          795084 2006/SO
          867953 2005/SO
L13           10 L12 NOT (2006/SO OR 2005/SO)
```

=> d l13 ibib hitstr abs 1-10

L13 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1329533 CAPLUS
DOCUMENT NUMBER: 146:87555
TITLE: Cetirizine hydrochloride masticatory tablet and its preparation
INVENTOR(S): Gu, Xuchu; Zhong, Xuebin
PATENT ASSIGNEE(S): Nanjing Golden Eagle Medicinery Technology Development Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 6pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1875970	A	20061213	CN 2005-10040439	20050608
PRIORITY APPLN. INFO.:			CN 2005-10040439	20050608

IT 83881-52-1, Cetirizine hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cetirizine hydrochloride masticatory tablet and its preparation)
RN 83881-52-1 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

AB The title masticatory tablet is composed of cetirizine hydrochloride 1, crystalline cellulose 10-50, sucrose 10-50, β-cyclodextrin 1-10, sodium carboxymethyl starch 1-10, sodium saccharin 0.2-5, magnesium stearate 0.1-10, micropowder silica gel 0.1-5 part, and water proper quantity. The preparation method comprises pulverizing, sieving by 80 mesh sieve, mixing cetirizine hydrochloride, sodium saccharin, β-cyclodextrin, sucrose powder, and crystalline cellulose with distilled water to obtain soft material, sieving by 40 mesh sieve, prilling, drying at 60° for 2 h, sieving by 30 mesh sieve, adding sodium carboxymethyl starch, magnesium stearate, and micropowder silica gel, stirring, and pressing. The invention can be used for treating seasonal or perennial allergic rhinitis, and urticaria and cutaneous pruritus caused by allergen.

L13 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:381409 CAPLUS
DOCUMENT NUMBER: 144:432829
TITLE: Preparation of 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin D2 receptor antagonists
INVENTOR(S): Lim, Sungtaek; Harris, Keith John; Stefany, David; Gardner, Charles J.; Cao, Bin; Boffey, Ray; Gillespy, Timothy A.; Aguiar, Joacy C.; Hunt, Hazel J.; Dechaux, Elsa A.

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 272 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044732	A2	20060427	WO 2005-US37148	20051014
WO 2006044732	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-619272P P 20041015
OTHER SOURCE(S): MARPAT 144:432829

IT 83881-51-0, Cetirizine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy agent; preparation of aminopyrimidines as prostaglandin D2 receptor antagonists)

RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



GI



I



II

AB The invention is directed to the preparation of aminopyrimidines I [Cy1 = (un)substituted cycloalkyl, heterocyclyl, hetero/aryl, etc.; Cy2 = (un)substituted cycloalkenyl, heterocyclenyl, hetero/aryl, etc.; L1 = cyclo/alkylene, CH2-haloalkylene; or L1Cy2 = arylcycloalkyl, cycloalkylaryl; R1 = alkylthio, NH2 and derivs., alkoxy; L2 = a bond, O, CH2O; provided that when R1 = OMe, L1 = CH2CH2, L2 = a bond, and Cy2 = 2,4-dichlorophenyl, then Cy1 is not 1-methyl-2-ethyloxycarbonylindol-5-yl], and their N-oxides, ester prodrugs, and their pharmaceutically acceptable salts, hydrates and solvates, and their use as prostaglandin D2 (PGD2) receptor antagonists in pharmaceutical compns. comprising a pharmaceutically effective amount of one or more compds. I in admixt. with a pharmaceutically acceptable carrier, and to a method of treating a patient suffering from a PGD2-mediated disorder. E.g., a 4-step synthesis, starting from from 3-fluoro-4-methoxybenzaldehyde, was given for pyrimidine II. Selected I produced 50% inhibition in the SPA cAMP assay in human LS174T cells expressing the endogenous DP receptor at concns. within the range of about 0.1 to about 30 nM. I are useful for treating allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch, diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis (no data).

L13 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:523256 CAPLUS
DOCUMENT NUMBER: 143:65406
TITLE: Multiparticulate crystalline drug compositions containing a Poloxamer and a glyceride
INVENTOR(S): Appel, Leah Elizabeth; Crew, Marshall David; Friesen, Dwayne Thomas; Herbig, Scott M.; Lo, Julian Belknap; Lyon, David Keith; McCray, Scott Bladwin; Ray, Roderick Jack; West, James Blair

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053652	A1	20050616	WO 2004-IB3808	20041122
WO 2005053652	A8	20050804		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005181062	A1	20050818	US 2004-4168	20041203

PRIORITY APPLN. INFO.: US 2003-527329P P 20031204

IT 83881-51-0, Cetirizine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(multiparticulate compns. containing glyceride and Poloxamer for controlled release of crystalline drug)

RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



AB A multiparticulate for controlled release of a crystalline drug comprises a glyceride having at least one alkylate substituent of at least 16 carbon atoms, and a Poloxamer, wherein at least 70 weight% of the drug in the multiparticulate is crystalline Thus, azithromycin-containing multiparticulates were prepared via a melt-congeal process from a mixture containing azithromycin/Compritol 888 ATO/Pluronic (50:40:10) forming a preblend and extrusion of the preblend at a feed rate of 130 g/min. More than 90 weight% of the azithromycin in the multiparticulates was crystalline dihydrate. The release rate of azithromycin from the multiparticulates was 32, 67, 90, 99, 99, and 100% in 5, 15, 30, 60, 120, and 180 min, resp.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:310383 CAPLUS
DOCUMENT NUMBER: 143:159082
TITLE: Preparation of inclusion complex of cetirizine-β-cyclodextrin
AUTHOR(S): Zhao, Liping; Cao, Deying; Feng, Xiangping; Yuan, Lihua
CORPORATE SOURCE: Pharmacy College, Hebei Medical University,

Shijiazhuang, 050017, Peop. Rep. China
SOURCE: Huaxi Yaoxue Zazhi (2004), 19(1), 30-32
CODEN: HYZAE2; ISSN: 1006-0103
PUBLISHER: Huaxi Yike Daxue Yaoxueyuan
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
IT 83881-52-1, Cetirizine hydrochloride
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of inclusion complex of cetirizine-β- cyclodextrin)
RN 83881-52-1 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

AB The inclusion compound of cetirizine-β-cyclodextrin was prepared and its properties were studied. The inclusion compound was prepared by saturated solution
method, and it was proved by the changes of physics properties before and after inclusion. The average inclusion rate of the inclusion compound was 85.1%. The UV spectra, solubility, taste, stability, X-ray diffractometry and IR spectra showed that the inclusion compound became a new complex. The inclusion compound of cetirizine-β-cyclodextrin could cover the no good taste of cetirizine.

L13 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:238545 CAPLUS
DOCUMENT NUMBER: 142:291446
TITLE: Methods and kits for monitoring resistance to therapeutic agents
INVENTOR(S): Cantor, Thomas L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005059023	A1	20050317	US 2003-664263	20030916
PRIORITY APPLN. INFO.:			US 2003-664263	20030916

IT 83881-51-0, Cetirizine 83881-52-1, ZYRTEC
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and kits for monitoring resistance to therapeutic agents)
RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 83881-52-1 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

AB The invention relates to novel methods and kits for monitoring the therapeutic inactivating capacity of a subject. The invention further relates to methods and kits for determining and/or monitoring a therapeutic protocol for a subject afflicted with auto-antibodies specific for a natural substance, wherein these auto antibodies develop as a result of therapeutic administration of the natural substance or an analog thereof. These methods and kits can be used, for example, to initiate, terminate, or adjust the level of administration of any of a variety of therapeutic agents.

L13 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:78236 CAPLUS
DOCUMENT NUMBER: 142:162672
TITLE: Crystalline cetirizine monohydrochloride
INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Rao, Uppala Venkata Bhaskara; Reddy, Konda Srinivasa
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020608	A1	20050127	US 2004-809192	20040325
IN 2003MA00252	A	20050304	IN 2003-MA252	20030325
PRIORITY APPLN. INFO.:			IN 2003-MA252 A	20030325

IT 798544-25-9P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 798544-25-9 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



IT 83881-52-1P, Cetirizine dihydrochloride
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline cetirizine monohydrochloride for oral dosage forms)
RN 83881-52-1 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

AB A novel crystalline form of cetirizine monohydrochloride and processes for making the crystalline form as well as compns., pharmaceutical compns., and methods utilizing the crystalline form are described. A process for preparation of a crystalline form of cetirizine monohydrochloride, comprises (1) providing a solid residue of crude cetirizine monohydrochloride; (2) contacting the crude residue with a ketone solvent to cause separation of a solid mass; and (3) isolating the solid mass thereby obtaining the crystalline form of cetirizine monohydrochloride. Tablets for the treatment of allergic syndromes were formulated containing crystalline cetirizine monohydrochloride 10, CaCO3 500, PVP 17, Avicel 15, mannitol 400, maltodextrin 15, aspartame 3, and aroma 20 mg each.

L13 ANSWER 7 OF 10 CAPLUS

ACCESSION NUMBER: 2004:1037084 CAPLUS
DOCUMENT NUMBER: 142:6558
TITLE: Preparation of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as antiallergic compound
INVENTOR(S): Singh, Shiva Prasad; Mukarram, Siddiqui Mohammed Jaweed; Merwade, Aravind Yekanathsa; Khan, Anjum Reyaz
PATENT ASSIGNEE(S): Wockhardt Limited, India
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103982	A1	20041202	WO 2003-IB1947	20030521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003228011	A1	20041213	AU 2003-228011	20030521
EP 1628964	A1	20060301	EP 2003-725479	20030521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 2006258684	A1	20061116	US 2006-554696	20060223
PRIORITY APPLN. INFO.:			WO 2003-IB1947 A	20030521

OTHER SOURCE(S): CASREACT 142:6558

IT 798544-25-9P
RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as antiallergic compound)

RN 798544-25-9 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



IT 83881-52-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as antiallergic compound)

RN 83881-52-1 CAPLUS

CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid monohydrochloride as antiallergic compound)
RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



AB The title compound (I) is prepared by reaction of 4-chlorobenzhydrylpiperazine with 2-chloroethanol followed by reaction with sodium chloroacetate and salt formation. I was characterized by DSC, NMR, X-ray powder diffraction, m.p., elemental anal., and HPLC.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:493694 CAPLUS
DOCUMENT NUMBER: 141:54360
TITLE: Polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation
INVENTOR(S): Reddy, Manne Satyanarayana; Srinivasan, Thirumalai Rajan; Uppala, Venkata Bhaskara Rao; Vaddadi, Pattabhi Ramayya; Joga, Rajender
PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050647	A2	20040617	WO 2003-US38494	20031204
WO 2004050647	A3	20040902		
WO 2004050647	A8	20050303		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2002MA00908	A	20050304	IN 2002-MA908		20021204	
CA 2488114	A1	20040617	CA 2003-2488114		20031204	
AU 2003297640	A1	20040623	AU 2003-297640		20031204	
US 2004186112	A1	20040923	US 2003-729856		20031204	
CN 1692105	A	20051102	CN 2003-80100543		20031204	
PRIORITY APPLN. INFO.:			IN 2002-MA908	A	20021204	
			WO 2003-US38494	W	20031204	

IT 130018-87-0P 163837-48-7P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation)
RN 130018-87-0 CAPLUS
CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



●2 HCl

RN 163837-48-7 CAPLUS
CN Acetic acid, [2-[4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



●2 HCl

IT 130018-76-7P, Dextrocetirizine 130018-77-8P, Levocetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(polymorphic crystalline forms of dihydrochloride salts of cetirizine and processes for their preparation from)

RN 130018-76-7 CAPLUS

CN Acetic acid, [2-[4-[(S)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 130018-77-8 CAPLUS

CN Acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



AB Crystalline polymorphic forms of the levorotatory and dextrorotatory cetirizine dihydrochloride salts are prepared by dissolving the salts in an a ketone-containing solvent (e.g., aqueous acetone), cooling the solution, and collecting the crystalline precipitate

L13 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:991495 CAPLUS

DOCUMENT NUMBER: 140:47519

TITLE: Process for the preparation of an amorphous form of [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)

INVENTOR(S): Reddy, Manne Satyanarayana; Rajan, Srinivasan Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu

PATENT ASSIGNEE(S): Dr.Reddy's Laboratories Ltd., India; Dr.Reddy's Laboratories, Inc.

SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104212	A1	20031218	WO 2003-US17600	20030604

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003238883	A1	20031222	AU 2003-238883	20030604
PRIORITY APPLN. INFO.:			IN 2002-MA425	A 20020605
			WO 2003-US17600	W 20030604

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in a process for the preparation of an amorphous form of [2-[4-[(4-chlorophenyl)phenylmethyl]-1- piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



IT 83881-52-1P, Cetirizine dihydrochloride
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(process for the preparation of an amorphous form of [2-[4-[(4-chlorophenyl)phenylmethyl]-1- piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))
RN 83881-52-1 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



AB A novel, amorphous form of [2-[4-[(4-Chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, suitable for pharmaceutical formulations, is prepared and X-ray diffraction patterns for it are presented.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:991494 CAPLUS
DOCUMENT NUMBER:	140:42205
TITLE:	Preparation of crystalline [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride)
INVENTOR(S):	Reddy, Manne Satyanarayana; Rajan, Srinivasan

Thirumalai; Shankar, Ranga Ravi; Vardhan, Sunkara Vishnu

PATENT ASSIGNEE(S): Reddy's Laboratories Limited, India; Reddy's Laboratories, Inc.

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104211	A2	20031218	WO 2003-US17672	20030604
WO 2003104211	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003237394	A1	20031222	AU 2003-237394	20030604

PRIORITY APPLN. INFO.:

IN 2002-MA425	A	20020605
WO 2003-US17672	W	20030604

OTHER SOURCE(S): CASREACT 140:42205

IT 83881-52-1P, Cetirizine dihydrochloride
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of crystalline [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride (cetirizine dihydrochloride))

RN 83881-52-1 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT 83881-51-0P, Cetirizine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(salification with HCl of)

RN 83881-51-0 CAPLUS
CN Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]- (9CI) (CA INDEX NAME)



AB A crystalline form of cetirizine dihydrochloride (I), prepared by the salification of cetirizine with isopropanolic hydrogen chloride, having a defined X-ray diffraction pattern is presented, and pharmaceutical compns. containing I are presented.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	75.02	247.33
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.80	-7.80

STN INTERNATIONAL LOGOFF AT 18:47:34 ON 23 FEB 2007